Shopping Cart 0
Cart Subtotal
USD 0

Amgen, Inc. - Strategy, SWOT and Corporate Finance Report

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 525
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Amgen, Inc.-Strategy, SWOT and Corporate Finance Report

Summary

Amgen, Inc.-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Key Highlights

Amgen, Inc., (Amgen or 'the company') is a biotechnology company involved in the discovery, development, manufacture, and marketing of human therapeutics. The company has expertise in the areas of cancer, kidney disease, rheumatoid arthritis and other serious illnesses. Its product portfolio includes Prolia(denosumab), XGEVA(denosumab), EVENITY (romosozumab), Repatha (evolocumab), Aimovig (erenumab), Aranesp (darbepoetin alfa), BLINCYTO (blinatumomab), KYPROLIS(carfilzomib), Vectibix (panitumumab), Sensipar/Mimpara (cinacalcet), and AMJEVITA (adalimumab-atto)/AMGEVITA (biosimilar adalimumab). The company has business presence across the US,Europe, LatinAmerica, the Middle East and Asia-Pacific. Amgen is headquartered in Thousand Oaks, California, the US.

Scope

- Detailed information on Amgen, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Amgen, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Amgen, Inc. including a breakdown and examination of key business segments

- Intelligence on Amgen, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Amgen, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of Amgen, Inc. and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess Amgen, Inc. as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on Amgen, Inc.'s business structure, strategy and prospects.

READ MORE

Table Of Content

Scope

Table of Contents

Company Snapshot 2

Table of Contents 5

Amgen, Inc.: Company Overview 9

Amgen, Inc.: Overview and Key Facts 9

Amgen, Inc.: Overview 9

Amgen, Inc.: Key Facts 9

Amgen, Inc.: Key Employees 11

Amgen, Inc.: Key Employee Biographies 13

Amgen, Inc.: Major Products and Services 20

Amgen, Inc.: Company History 21

Amgen, Inc.: Management Statement 29

Amgen, Inc.: Locations and Subsidiaries 34

Amgen, Inc.: Key Competitors 36

Amgen, Inc.: Company Analysis 37

Amgen, Inc.: Business Description 37

Amgen, Inc.: SWOT Analysis 40

Amgen, Inc.: SWOT Overview 40

Amgen, Inc.: Strengths 40

Amgen, Inc.: Weaknesses 41

Amgen, Inc.: Opportunities 41

Amgen, Inc.: Threats 42

Amgen, Inc.: Corporate Financial Deals Activity 44

Amgen, Inc.: Financial Deals Overview 44

Amgen, Inc.: Targets and Partners 46

Amgen, Inc.: Top Deals 2014-2018YTD 48

Amgen, Inc.: Advisors 49

Amgen, Inc.: Top Legal Advisors 49

Amgen, Inc.: Top Financial Advisors 49

Amgen, Inc.: Mergers and Acquisitions 51

Amgen, Inc.: Corporate Venturing 52

Amgen, Inc.: Capital Raising 53

Amgen, Inc.: Partnership 54

Amgen, Inc.: Divestments 55

Amgen, Inc.: Recent Developments 56

Amgen, Inc.: News and Events Summary 56

Amgen, Inc.: Business Expansion 61

Amgen, Inc.: Contracts 62

Amgen, Inc.: Corporate Governance 63

Amgen, Inc.: Financial Performance 64

Amgen, Inc.: Strategy and Operations 64

Appendix 66

Contact Us 66

Methodology 66

About MarketLine 67


List Of Figure

List of Figures

Figure 1: Amgen, Inc.: Deal Activity by Deal Type-Volume (TTM )

Figure 2: Amgen, Inc.: M&A Activity by Geography (TTM )

Figure 3: Amgen, Inc.: Deal Activity by Deal Type-Volume (2014-YTD 2018)

Figure 4: Amgen, Inc.: M&A Average Deal Size-Value (USD m)

Figure 5: Amgen, Inc.: M&A Volume and Value Trend (2014-YTD 2018)

Figure 6: Amgen, Inc.: M&A Activity by Geography (2014-YTD 2018)

Figure 7: Amgen, Inc.: Corporate Venturing Volume and Value Trend (2014-YTD 2018)

Figure 8: Amgen, Inc.: Corporate Venturing by Geography (2014-YTD 2018)

Figure 9: Amgen, Inc.: Capital Raising Volume and Value Trend (2014-YTD 2018)

Figure 10: Amgen, Inc.: Capital Raising by Deal Type (2014-YTD 2018)

Figure 11: Amgen, Inc.: Partnership Volume and Value Trend (2014-YTD 2018)

Figure 12: Amgen, Inc.: Partnership Trend by Deal Type (2014-YTD 2018)

Figure 13: Amgen, Inc.: Divestments Volume and Value Trend (2014-YTD 2018)


List Of Table

List of Tables

Table 1: Amgen, Inc.: Key Facts

Table 2: Amgen, Inc.: Key Employees

Table 3: Amgen, Inc.: Locations and Subsidiaries

Table 4: Amgen, Inc.: Key Competitors

Table 5: Amgen, Inc.: Deal Activity by Deal Type-Volume (TTM )

Table 6: Amgen, Inc.: M&A Activity by Geography (TTM )

Table 7: Amgen, Inc.: Deal Activity by Deal Type-Volume (2014-YTD 2018)

Table 8: Amgen, Inc.: M&A Average Deal Size-Value (USD m)

Table 9: Amgen, Inc.: Targets and Partners

Table 10: Amgen, Inc.: Top Deals 2014-2018YTD

Table 11: Amgen, Inc.: Legal Advisor Ranking by Value (USD m)

Table 12: Amgen, Inc.: Financial Advisor Ranking by Value (USD m)

Table 13: Amgen, Inc.: M&A Volume and Value Trend (2014-YTD 2018)

Table 14: Amgen, Inc.: M&A Activity by Geography (2014-YTD 2018)

Table 15: Amgen, Inc.: Corporate Venturing Volume and Value Trend (2014-YTD 2018)

Table 16: Amgen, Inc.: Corporate Venturing by Geography (2014-YTD 2018)

Table 17: Amgen, Inc.: Capital Raising Volume and Value Trend (2014-YTD 2018)

Table 18: Amgen, Inc.: Capital Raising by Deal Type (2014-YTD 2018)

Table 19: Amgen, Inc.: Partnership Volume and Value Trend (2014-YTD 2018)

Table 20: Amgen, Inc.: Partnership Trend by Deal Type (2014-YTD 2018)

Table 21: Amgen, Inc.: Divestments Volume and Value Trend (2014-YTD 2018)

Table 22: Amgen, Inc.: News and Events Summary

Table 23: Amgen, Inc.: Business Expansion

Table 24: Amgen, Inc.: Contracts

Table 25: Amgen, Inc.: Corporate Governance

Table 26: Amgen, Inc.: Financial Performance

Table 27: Amgen, Inc.: Strategy and Operations

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Amgen, Inc.-Strategy, SWOT and Corporate Finance Report

Summary

Amgen, Inc.-Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Key Highlights

Amgen, Inc., (Amgen or 'the company') is a biotechnology company involved in the discovery, development, manufacture, and marketing of human therapeutics. The company has expertise in the areas of cancer, kidney disease, rheumatoid arthritis and other serious illnesses. Its product portfolio includes Prolia(denosumab), XGEVA(denosumab), EVENITY (romosozumab), Repatha (evolocumab), Aimovig (erenumab), Aranesp (darbepoetin alfa), BLINCYTO (blinatumomab), KYPROLIS(carfilzomib), Vectibix (panitumumab), Sensipar/Mimpara (cinacalcet), and AMJEVITA (adalimumab-atto)/AMGEVITA (biosimilar adalimumab). The company has business presence across the US,Europe, LatinAmerica, the Middle East and Asia-Pacific. Amgen is headquartered in Thousand Oaks, California, the US.

Scope

- Detailed information on Amgen, Inc. required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Amgen, Inc. in the form of a SWOT analysis

- An in-depth view of the business model of Amgen, Inc. including a breakdown and examination of key business segments

- Intelligence on Amgen, Inc.'s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Amgen, Inc., such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of Amgen, Inc. and the factors that influence its strategies.

- Track strategic initiatives of the company and latest corporate news and actions.

- Assess Amgen, Inc. as a prospective partner, vendor or supplier.

- Support sales activities by understanding your customers' businesses better.

- Stay up to date on Amgen, Inc.'s business structure, strategy and prospects.

READ MORE

Scope

Table of Contents

Company Snapshot 2

Table of Contents 5

Amgen, Inc.: Company Overview 9

Amgen, Inc.: Overview and Key Facts 9

Amgen, Inc.: Overview 9

Amgen, Inc.: Key Facts 9

Amgen, Inc.: Key Employees 11

Amgen, Inc.: Key Employee Biographies 13

Amgen, Inc.: Major Products and Services 20

Amgen, Inc.: Company History 21

Amgen, Inc.: Management Statement 29

Amgen, Inc.: Locations and Subsidiaries 34

Amgen, Inc.: Key Competitors 36

Amgen, Inc.: Company Analysis 37

Amgen, Inc.: Business Description 37

Amgen, Inc.: SWOT Analysis 40

Amgen, Inc.: SWOT Overview 40

Amgen, Inc.: Strengths 40

Amgen, Inc.: Weaknesses 41

Amgen, Inc.: Opportunities 41

Amgen, Inc.: Threats 42

Amgen, Inc.: Corporate Financial Deals Activity 44

Amgen, Inc.: Financial Deals Overview 44

Amgen, Inc.: Targets and Partners 46

Amgen, Inc.: Top Deals 2014-2018YTD 48

Amgen, Inc.: Advisors 49

Amgen, Inc.: Top Legal Advisors 49

Amgen, Inc.: Top Financial Advisors 49

Amgen, Inc.: Mergers and Acquisitions 51

Amgen, Inc.: Corporate Venturing 52

Amgen, Inc.: Capital Raising 53

Amgen, Inc.: Partnership 54

Amgen, Inc.: Divestments 55

Amgen, Inc.: Recent Developments 56

Amgen, Inc.: News and Events Summary 56

Amgen, Inc.: Business Expansion 61

Amgen, Inc.: Contracts 62

Amgen, Inc.: Corporate Governance 63

Amgen, Inc.: Financial Performance 64

Amgen, Inc.: Strategy and Operations 64

Appendix 66

Contact Us 66

Methodology 66

About MarketLine 67


List Of Figure

List of Figures

Figure 1: Amgen, Inc.: Deal Activity by Deal Type-Volume (TTM )

Figure 2: Amgen, Inc.: M&A Activity by Geography (TTM )

Figure 3: Amgen, Inc.: Deal Activity by Deal Type-Volume (2014-YTD 2018)

Figure 4: Amgen, Inc.: M&A Average Deal Size-Value (USD m)

Figure 5: Amgen, Inc.: M&A Volume and Value Trend (2014-YTD 2018)

Figure 6: Amgen, Inc.: M&A Activity by Geography (2014-YTD 2018)

Figure 7: Amgen, Inc.: Corporate Venturing Volume and Value Trend (2014-YTD 2018)

Figure 8: Amgen, Inc.: Corporate Venturing by Geography (2014-YTD 2018)

Figure 9: Amgen, Inc.: Capital Raising Volume and Value Trend (2014-YTD 2018)

Figure 10: Amgen, Inc.: Capital Raising by Deal Type (2014-YTD 2018)

Figure 11: Amgen, Inc.: Partnership Volume and Value Trend (2014-YTD 2018)

Figure 12: Amgen, Inc.: Partnership Trend by Deal Type (2014-YTD 2018)

Figure 13: Amgen, Inc.: Divestments Volume and Value Trend (2014-YTD 2018)


List Of Table

List of Tables

Table 1: Amgen, Inc.: Key Facts

Table 2: Amgen, Inc.: Key Employees

Table 3: Amgen, Inc.: Locations and Subsidiaries

Table 4: Amgen, Inc.: Key Competitors

Table 5: Amgen, Inc.: Deal Activity by Deal Type-Volume (TTM )

Table 6: Amgen, Inc.: M&A Activity by Geography (TTM )

Table 7: Amgen, Inc.: Deal Activity by Deal Type-Volume (2014-YTD 2018)

Table 8: Amgen, Inc.: M&A Average Deal Size-Value (USD m)

Table 9: Amgen, Inc.: Targets and Partners

Table 10: Amgen, Inc.: Top Deals 2014-2018YTD

Table 11: Amgen, Inc.: Legal Advisor Ranking by Value (USD m)

Table 12: Amgen, Inc.: Financial Advisor Ranking by Value (USD m)

Table 13: Amgen, Inc.: M&A Volume and Value Trend (2014-YTD 2018)

Table 14: Amgen, Inc.: M&A Activity by Geography (2014-YTD 2018)

Table 15: Amgen, Inc.: Corporate Venturing Volume and Value Trend (2014-YTD 2018)

Table 16: Amgen, Inc.: Corporate Venturing by Geography (2014-YTD 2018)

Table 17: Amgen, Inc.: Capital Raising Volume and Value Trend (2014-YTD 2018)

Table 18: Amgen, Inc.: Capital Raising by Deal Type (2014-YTD 2018)

Table 19: Amgen, Inc.: Partnership Volume and Value Trend (2014-YTD 2018)

Table 20: Amgen, Inc.: Partnership Trend by Deal Type (2014-YTD 2018)

Table 21: Amgen, Inc.: Divestments Volume and Value Trend (2014-YTD 2018)

Table 22: Amgen, Inc.: News and Events Summary

Table 23: Amgen, Inc.: Business Expansion

Table 24: Amgen, Inc.: Contracts

Table 25: Amgen, Inc.: Corporate Governance

Table 26: Amgen, Inc.: Financial Performance

Table 27: Amgen, Inc.: Strategy and Operations

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com